123 related articles for article (PubMed ID: 1856142)
1. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study.
Meunier F; Van der Auwera P; Aoun M; Ibrahim S; Tulkens PM
J Antimicrob Chemother; 1991 May; 27 Suppl C():129-39. PubMed ID: 1856142
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer.
Pession A; Prete A; Paolucci G
Chemotherapy; 1997; 43(5):358-66. PubMed ID: 9309370
[TBL] [Abstract][Full Text] [Related]
3. Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients.
Cudillo L; Masi M; Scimò MT; Tribalto M; Cantonetti M; Criscuolo D; Papa G
J Chemother; 1989 Dec; 1(6):413-6. PubMed ID: 2614507
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
Ann Intern Med; 1993 Oct; 119(7 Pt 1):584-93. PubMed ID: 8363169
[TBL] [Abstract][Full Text] [Related]
5. Netilmicin plus ceftriaxone versus amikacin plus ceftriaxone in the treatment of infections in granulocytopenic patients.
Krcméry V; Koza I; Mardiak J; Fuchsberger P; Spánik S; Trupl J; Horníková M; Kusenda Z; Sufliarsky J; Svec J
Chemotherapy; 1992; 38(1):74-6. PubMed ID: 1618007
[TBL] [Abstract][Full Text] [Related]
6. Strategies for cost-containment: once-daily ceftriaxone plus amikacin as empiric therapy for febrile granulocytopenic children with cancer.
Castagnola E; Lanino E; Giacchino R; Viscoli C; Dini G
J Chemother; 1999 Feb; 11(1):54-60. PubMed ID: 10078782
[TBL] [Abstract][Full Text] [Related]
7. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group.
Meunier F; Zinner SH; Gaya H; Calandra T; Viscoli C; Klastersky J; Glauser M
Antimicrob Agents Chemother; 1991 May; 35(5):873-8. PubMed ID: 1854169
[TBL] [Abstract][Full Text] [Related]
9. Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia.
Schmid L; Jeschko M; Wilder-Smith C; Schafroth U; Thürlimann B; Pedrazzini A; Senn H
Chemotherapy; 1991; 37(5):346-52. PubMed ID: 1804595
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients.
Liu CY; Wang FD
Chemotherapy; 1989; 35 Suppl 2():16-22. PubMed ID: 2692982
[TBL] [Abstract][Full Text] [Related]
11. Ceftriaxone and amikacin as single daily dose in the empiric therapy for febrile episodes in neutropenic patients.
Martino P; Girmenia C; Raccah R; Micozzi A; Cimino G; Mandelli F
Haematologica; 1990; 75(1):69-74. PubMed ID: 2338290
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group.
J Infect Dis; 1991 May; 163(5):951-8. PubMed ID: 2019772
[TBL] [Abstract][Full Text] [Related]
13. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC
Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269
[TBL] [Abstract][Full Text] [Related]
14. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
Charnas R; Lüthi AR; Ruch W
Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
[TBL] [Abstract][Full Text] [Related]
15. Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone.
Suwangool P; Aswapokee N; Sathapatayavongs B; Leelasuphasri S; Siritanaratkul N; Chuncharunee S; Chayakul P
J Med Assoc Thai; 1993 Jun; 76(6):314-8. PubMed ID: 8083623
[TBL] [Abstract][Full Text] [Related]
16. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients.
Leoni F; Ciolli S; Pascarella A; Fanci R; Caporale R; Rossi Ferrini P
Chemotherapy; 1993; 39(2):147-52. PubMed ID: 8458248
[TBL] [Abstract][Full Text] [Related]
17. Piperacillin plus amikacin therapy v carbenicillin plus amikacin therapy in febrile, granulocytopenic patients.
Winston DJ; Ho WG; Young LS; Hewitt WL; Gale RP
Arch Intern Med; 1982 Sep; 142(9):1663-7. PubMed ID: 6214228
[TBL] [Abstract][Full Text] [Related]
18. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
[TBL] [Abstract][Full Text] [Related]
19. Empiric antimicrobial therapy in febrile granulocytopenic patients. Randomized prospective comparison of amikacin plus piperacillin with or without parenteral trimethoprim/sulphamethoxazole.
Menichetti F; Del Favero A; Guerciolini R; Tonato M; Aversa F; Roila F; Frongillo RF; Martelli MF; Davis S; Pauluzzi S
Infection; 1986; 14(6):261-7. PubMed ID: 3546144
[TBL] [Abstract][Full Text] [Related]
20. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients.
Winston DJ; Barnes RC; Ho WG; Young LS; Champlin RE; Gale RP
Am J Med; 1984 Sep; 77(3):442-50. PubMed ID: 6475984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
